Literature DB >> 12834914

Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain.

R A Nicholson1, C Liao, J Zheng, L S David, L Coyne, A C Errington, G Singh, G Lees.   

Abstract

Anandamide is a prominent member of the endocannabinoids, a group of diffusible lipid molecules which influences neuronal excitability. In this context, endocannabinoids are known to modulate certain presynaptic Ca(2+) and K(+) channels, either through cannabinoid (CB1) receptor stimulation and second messenger pathway activation or by direct action. We investigated the susceptibility of voltage-sensitive sodium channels to anandamide and other cannibimimetics using both biochemical and electrophysiological approaches. Here we report that anandamide, AM 404 and WIN 55,212-2 inhibit veratridine-dependent depolarization of synaptoneurosomes (IC(50)s, respectively 21.8, 9.3 and 21.1 microM) and veratridine-dependent release of L-glutamic acid and GABA from purified synaptosomes [IC(50)s: 5.1 microM (L-glu) and 16.5 microM (GABA) for anandamide; 1.6 microM (L-glu) and 3.3 microM (GABA) for AM 404, and 12.2 (L-glu) and 14.4 microM (GABA) for WIN 55,212-2]. The binding of [3H]batrachotoxinin A 20-alpha-benzoate to voltage-sensitive sodium channels was also inhibited by low to mid micromolar concentrations of anandamide, AM 404 and WIN 55,212-2. In addition, anandamide (10 microM), AM 404 (10 microM) and WIN 55,212-2 (1 microM) were found to markedly block TTX-sensitive sustained repetitive firing in cortical neurones without altering primary spikes, consistent with a state-dependent mechanism. None of the inhibitory effects we demonstrate on voltage-sensitive sodium channels are attenuated by the potent CB1 antagonist AM 251 (1-2 microM). Anandamide's action is reversible and its effects are enhanced by fatty acid amidohydrolase inhibition. We propose that voltage-sensitive sodium channels may participate in a novel signaling pathway involving anandamide. This mechanism has potential to depress synaptic transmission in brain by damping neuronal capacity to support action potentials and reducing evoked release of both excitatory and inhibitory transmitters.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834914     DOI: 10.1016/s0006-8993(03)02808-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  31 in total

Review 1.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Ghrelin-induced activation of cAMP signal transduction and its negative regulation by endocannabinoids in the hippocampus.

Authors:  Jacquelynn N Cuellar; Masako Isokawa
Journal:  Neuropharmacology       Date:  2010-12-25       Impact factor: 5.250

Review 4.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 5.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 6.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

7.  Evidence for bidirectional endocannabinoid transport across cell membranes.

Authors:  Andrea Chicca; Janine Marazzi; Simon Nicolussi; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

8.  Alterations in the intrinsic burst activity of Purkinje neurons in offspring maternally exposed to the CB1 cannabinoid agonist WIN 55212-2.

Authors:  Mohammad Shabani; Amin Mahnam; Vahid Sheibani; Mahyar Janahmadi
Journal:  J Membr Biol       Date:  2013-11-12       Impact factor: 1.843

9.  The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.

Authors:  Murat Oz; Vanaja Jaligam; Sehamuddin Galadari; George Petroianu; Yaroslav M Shuba; Toni S Shippenberg
Journal:  J Neurochem       Date:  2009-12-24       Impact factor: 5.372

Review 10.  The pharmacology of the cannabinoid system--a question of efficacy and selectivity.

Authors:  Christopher J Fowler
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.